

ICD-10 Procedure Coding System (ICD-10-PCS) 2025 Tables Addenda

ICD-10-PCS Tables that have changed this year are shown in table format in the pages below. Click on a bookmark to go to a specific table.

Each table shown in the addenda replaces the table from the previous year.

0B1

No change	<i>Section</i> 0 Medical and Surgical			
	<i>Body System</i> B Respiratory System			
	<i>Operation</i> 1 Bypass: Altering the route of passage of the contents of a tubular body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
No change	1 Trachea	0 Open	D Intraluminal Device	6 Esophagus
No change	1 Trachea	0 Open	F Tracheostomy Device Z No Device	4 Cutaneous
No change	1 Trachea	3 Percutaneous 4 Percutaneous Endoscopic	F Tracheostomy Device Z No Device	4 Cutaneous
FY2025	1 Trachea	8 Via Natural or Artificial Opening Endoscopic	D Intraluminal Device	6 Esophagus

0CY

FY2025	<i>Section</i>	0	Medical and Surgical		
	<i>Body System</i>	C	Mouth and Throat		
	<i>Operation</i>	Y	Transplantation: Putting in or on all or a portion of a living body part taken from another individual or animal to physically take the place and/or function of all or a portion of a similar body part		
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>	
FY2025	S Larynx	0 Open	Z No Device	0 Allogeneic 1 Syngeneic	

ODX

No change	Section 0 Medical and Surgical Body System D Gastrointestinal System Operation X Transfer: Moving, without taking out, all or a portion of a body part to another location to take over the function of all or a portion of a body part			
Heading	Body Part	Approach	Device	Qualifier
No change	6 Stomach	0 Open 4 Percutaneous Endoscopic	Z No Device	5 Esophagus
FY2025	8 Small Intestine	0 Open 4 Percutaneous Endoscopic	Z No Device	5 Esophagus 7 Vagina B Bladder C Ureter, Right D Ureter, Left F Ureters, Bilateral
No change	E Large Intestine	0 Open 4 Percutaneous Endoscopic	Z No Device	5 Esophagus 7 Vagina B Bladder
No change	U Omentum	0 Open 4 Percutaneous Endoscopic	Z No Device	V Thoracic Region W Abdominal Region X Pelvic Region Y Inguinal Region

OSG

No change	<i>Section</i>	0	Medical and Surgical	
	<i>Body System</i>	S	Lower Joints	
	<i>Operation</i>	G	Fusion: Joining together portions of an articular body part rendering the articular body part immobile	
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
No change	0 Lumbar Vertebral Joint 1 Lumbar Vertebral Joints, 2 or more 3 Lumbosacral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	0 Anterior Approach, Anterior Column 1 Posterior Approach, Posterior Column J Posterior Approach, Anterior Column
No change	0 Lumbar Vertebral Joint 1 Lumbar Vertebral Joints, 2 or more 3 Lumbosacral Joint	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	A Interbody Fusion Device	0 Anterior Approach, Anterior Column J Posterior Approach, Anterior Column
FY2025	5 Sacrococcygeal Joint 7 Sacroiliac Joint, Right 8 Sacroiliac Joint, Left	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	4 Internal Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	Z No Qualifier
No change	9 Hip Joint, Right B Hip Joint, Left C Knee Joint, Right D Knee Joint, Left F Ankle Joint, Right G Ankle Joint, Left H Tarsal Joint, Right J Tarsal Joint, Left K Tarsometatarsal Joint, Right L Tarsometatarsal Joint, Left M Metatarsal-Phalangeal Joint, Right N Metatarsal-Phalangeal Joint, Left P Toe Phalangeal Joint, Right Q Toe Phalangeal Joint, Left	0 Open 3 Percutaneous 4 Percutaneous Endoscopic	3 Internal Fixation Device, Sustained Compression 4 Internal Fixation Device 5 External Fixation Device 7 Autologous Tissue Substitute J Synthetic Substitute K Nonautologous Tissue Substitute	Z No Qualifier

OTT

No change	Section 0 Medical and Surgical			
	Body System T Urinary System			
	Operation T Resection: Cutting out or off, without replacement, all of a body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
FY2025	0 Kidney, Right 1 Kidney, Left	0 Open	Z No Device	0 Allogeneic 1 Syngeneic 2 Zooplastic Z No Qualifier
FY2025	0 Kidney, Right 1 Kidney, Left	4 Percutaneous Endoscopic	Z No Device	G Hand-Assisted Z No Qualifier
FY2025	2 Kidneys, Bilateral	0 Open	Z No Device	Z No Qualifier
FY2025	2 Kidneys, Bilateral	4 Percutaneous Endoscopic	Z No Device	G Hand-Assisted Z No Qualifier
No change	3 Kidney Pelvis, Right 4 Kidney Pelvis, Left 6 Ureter, Right 7 Ureter, Left B Bladder C Bladder Neck D Urethra	0 Open 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	Z No Qualifier

0U7

No change	<i>Section</i> 0 Medical and Surgical			
	<i>Body System</i> U Female Reproductive System			
	<i>Operation</i> 7 Dilation: Expanding an orifice or the lumen of a tubular body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device</i>	<i>Qualifier</i>
FY2025	5 Fallopian Tube, Right 6 Fallopian Tube, Left 7 Fallopian Tubes, Bilateral 9 Uterus G Vagina	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	D Intraluminal Device Z No Device	Z No Qualifier
FY2025	C Cervix	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 8 Via Natural or Artificial Opening Endoscopic	D Intraluminal Device Z No Device	Z No Qualifier
FY2025	C Cervix	7 Via Natural or Artificial Opening	D Intraluminal Device	J Temporary Z No Qualifier
FY2025	C Cervix	7 Via Natural or Artificial Opening	Z No Device	Z No Qualifier
No change	K Hymen	0 Open 3 Percutaneous 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic X External	D Intraluminal Device Z No Device	Z No Qualifier

10D

No change	Section 1 Obstetrics Body System 0 Pregnancy Operation D Extraction: Pulling or stripping out or off all or a portion of a body part by the use of force			
Heading	Body Part	Approach	Device	Qualifier
No change	0 Products of Conception	0 Open	Z No Device	0 High 1 Low 2 Extraperitoneal
No change	0 Products of Conception	7 Via Natural or Artificial Opening	Z No Device	3 Low Forceps 4 Mid Forceps 5 High Forceps 6 Vacuum 7 Internal Version 8 Other
FY2025	1 Products of Conception, Retained	0 Open	Z No Device	Z No Qualifier
No change	1 Products of Conception, Retained	7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	9 Manual Z No Qualifier
No change	2 Products of Conception, Ectopic	0 Open 4 Percutaneous Endoscopic 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	Z No Device	Z No Qualifier

3E0

No change	Section 3 Administration Body System E Physiological Systems and Anatomical Regions Operation 0 Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products			
	Heading	Body System / Region	Approach	Substance
	Qualifier			
No change	0 Skin and Mucous Membranes	X External	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	0 Skin and Mucous Membranes	X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	0 Skin and Mucous Membranes	X External	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine B Anesthetic Agent K Other Diagnostic Substance M Pigment N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	0 Skin and Mucous Membranes	X External	G Other Therapeutic Substance	C Other Substance
No change	1 Subcutaneous Tissue	0 Open	2 Anti-infective	A Anti-Infective Envelope
No change	1 Subcutaneous Tissue	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	1 Subcutaneous Tissue	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective A Anti-Infective Envelope
No change	1 Subcutaneous Tissue	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	1 Subcutaneous Tissue	3 Percutaneous	4 Serum, Toxoid and Vaccine	0 Influenza Vaccine Z No Qualifier
No change	1 Subcutaneous Tissue	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	1 Subcutaneous Tissue	3 Percutaneous	V Hormone	G Insulin J Other Hormone
No change	2 Muscle	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	2 Muscle	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	2 Muscle	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier

No change	2 Muscle	3 Percutaneous	4 Serum, Toxoid and Vaccine	0 Influenza Vaccine Z No Qualifier
No change	2 Muscle	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	3 Peripheral Vein	0 Open	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	3 Peripheral Vein	0 Open	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	3 Peripheral Vein	0 Open	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	3 Peripheral Vein	0 Open	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	3 Peripheral Vein	0 Open	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption
No change	3 Peripheral Vein	0 Open	U Pancreatic Islet Cells	0 Autologous 1 Nonautologous
No change	3 Peripheral Vein	0 Open	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	3 Peripheral Vein	0 Open	W Immunotherapeutic	K Immunostimulator L Immunosuppressive
No change	3 Peripheral Vein	3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	3 Peripheral Vein	3 Percutaneous	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	3 Peripheral Vein	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	3 Peripheral Vein	3 Percutaneous	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	3 Peripheral Vein	3 Percutaneous	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption Q Glucarpidase R Other Therapeutic Monoclonal Antibody
No change	3 Peripheral Vein	3 Percutaneous	U Pancreatic Islet Cells	0 Autologous 1 Nonautologous
No change	3 Peripheral Vein	3 Percutaneous	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	3 Peripheral Vein	3 Percutaneous	W Immunotherapeutic	K Immunostimulator L Immunosuppressive
No change	4 Central Vein	0 Open	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	4 Central Vein	0 Open	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	4 Central Vein	0 Open	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	4 Central Vein	0 Open	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	4 Central Vein	0 Open	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption
No change	4 Central Vein	0 Open	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	4 Central Vein	0 Open	W Immunotherapeutic	K Immunostimulator L Immunosuppressive

No change	4 Central Vein	3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	4 Central Vein	3 Percutaneous	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	4 Central Vein	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	4 Central Vein	3 Percutaneous	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	4 Central Vein	3 Percutaneous	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption Q Glucarpidase R Other Therapeutic Monoclonal Antibody
No change	4 Central Vein	3 Percutaneous	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	4 Central Vein	3 Percutaneous	W Immunotherapeutic	K Immunostimulator L Immunosuppressive
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 5 Other Antineoplastic M Monoclonal Antibody P Clofarabine
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance F Intracirculatory Anesthetic H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives P Platelet Inhibitor R Antiarrhythmic T Destructive Agent X Vasopressor	Z No Qualifier
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	G Other Therapeutic Substance	C Other Substance N Blood Brain Barrier Disruption

No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	V Hormone	G Insulin H Human B-type Natriuretic Peptide J Other Hormone
No change	5 Peripheral Artery 6 Central Artery	0 Open 3 Percutaneous	W Immunotherapeutic	K Immunostimulator L Immunosuppressive
No change	7 Coronary Artery 8 Heart	0 Open 3 Percutaneous	1 Thrombolytic	6 Recombinant Human-activated Protein C 7 Other Thrombolytic
No change	7 Coronary Artery 8 Heart	0 Open 3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	7 Coronary Artery 8 Heart	0 Open 3 Percutaneous	K Other Diagnostic Substance P Platelet Inhibitor	Z No Qualifier
No change	7 Coronary Artery 8 Heart	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	9 Nose	3 Percutaneous 7 Via Natural or Artificial Opening X External	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	9 Nose	3 Percutaneous 7 Via Natural or Artificial Opening X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	9 Nose	3 Percutaneous 7 Via Natural or Artificial Opening X External	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	9 Nose	3 Percutaneous 7 Via Natural or Artificial Opening X External	G Other Therapeutic Substance	C Other Substance
No change	A Bone Marrow	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	A Bone Marrow	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	B Ear	3 Percutaneous 7 Via Natural or Artificial Opening X External	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	B Ear	3 Percutaneous 7 Via Natural or Artificial Opening X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	B Ear	3 Percutaneous 7 Via Natural or Artificial Opening X External	3 Anti-inflammatory B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	B Ear	3 Percutaneous 7 Via Natural or Artificial Opening X External	G Other Therapeutic Substance	C Other Substance

No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	3 Anti-inflammatory B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance M Pigment N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	G Other Therapeutic Substance	C Other Substance
No change	C Eye	3 Percutaneous 7 Via Natural or Artificial Opening X External	S Gas	F Other Gas
No change	D Mouth and Pharynx	3 Percutaneous 7 Via Natural or Artificial Opening X External	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	D Mouth and Pharynx	3 Percutaneous 7 Via Natural or Artificial Opening X External	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	D Mouth and Pharynx	3 Percutaneous 7 Via Natural or Artificial Opening X External	3 Anti-inflammatory 4 Serum, Toxoid and Vaccine 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives R Antiarrhythmic T Destructive Agent	Z No Qualifier
No change	D Mouth and Pharynx	3 Percutaneous 7 Via Natural or Artificial Opening X External	G Other Therapeutic Substance	C Other Substance
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	S Gas	F Other Gas
No change	E Products of Conception G Upper GI H Lower GI K Genitourinary Tract N Male Reproductive	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	F Respiratory Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	S Gas	D Nitric Oxide F Other Gas
No change	F Respiratory Tract	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance

No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	S Gas	F Other Gas
No change	J Biliary and Pancreatic Tract	3 Percutaneous 7 Via Natural or Artificial Opening 8 Via Natural or Artificial Opening Endoscopic	U Pancreatic Islet Cells	0 Autologous 1 Nonautologous
No change	J Biliary and Pancreatic Tract	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	L Pleural Cavity	0 Open	5 Adhesion Barrier	Z No Qualifier
No change	L Pleural Cavity	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	L Pleural Cavity	3 Percutaneous	1 Thrombolytic	7 Other Thrombolytic
No change	L Pleural Cavity	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	L Pleural Cavity	3 Percutaneous	3 Anti-inflammatory 5 Adhesion Barrier 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	L Pleural Cavity	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	L Pleural Cavity	3 Percutaneous	S Gas	F Other Gas

No change	L Pleural Cavity	4 Percutaneous Endoscopic	5 Adhesion Barrier	Z No Qualifier
No change	L Pleural Cavity	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	L Pleural Cavity	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	L Pleural Cavity	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	M Peritoneal Cavity	0 Open	5 Adhesion Barrier	Z No Qualifier
No change	M Peritoneal Cavity	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody Y Hyperthermic
No change	M Peritoneal Cavity	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	M Peritoneal Cavity	3 Percutaneous	3 Anti-inflammatory 5 Adhesion Barrier 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	M Peritoneal Cavity	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	M Peritoneal Cavity	3 Percutaneous	S Gas	F Other Gas
No change	M Peritoneal Cavity	4 Percutaneous Endoscopic	5 Adhesion Barrier	Z No Qualifier
No change	M Peritoneal Cavity	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	M Peritoneal Cavity	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	M Peritoneal Cavity	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	P Female Reproductive	0 Open	5 Adhesion Barrier	Z No Qualifier
No change	P Female Reproductive	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	P Female Reproductive	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	P Female Reproductive	3 Percutaneous	3 Anti-inflammatory 5 Adhesion Barrier 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance L Sperm N Analgesics, Hypnotics, Sedatives T Destructive Agent V Hormone	Z No Qualifier

No change	P Female Reproductive	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	P Female Reproductive	3 Percutaneous	Q Fertilized Ovum	0 Autologous 1 Nonautologous
No change	P Female Reproductive	3 Percutaneous	S Gas	F Other Gas
No change	P Female Reproductive	4 Percutaneous Endoscopic	5 Adhesion Barrier	Z No Qualifier
No change	P Female Reproductive	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	P Female Reproductive	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	P Female Reproductive	7 Via Natural or Artificial Opening	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	P Female Reproductive	7 Via Natural or Artificial Opening	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance L Sperm N Analgesics, Hypnotics, Sedatives T Destructive Agent V Hormone	Z No Qualifier
No change	P Female Reproductive	7 Via Natural or Artificial Opening	G Other Therapeutic Substance	C Other Substance
No change	P Female Reproductive	7 Via Natural or Artificial Opening	Q Fertilized Ovum	0 Autologous 1 Nonautologous
No change	P Female Reproductive	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	P Female Reproductive	8 Via Natural or Artificial Opening Endoscopic	S Gas	F Other Gas
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance A Stem Cells, Embryonic B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	E Stem Cells, Somatic	0 Autologous 1 Nonautologous
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	Q Cranial Cavity and Brain	0 Open 3 Percutaneous	S Gas	F Other Gas
No change	Q Cranial Cavity and Brain	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	Q Cranial Cavity and Brain	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	R Spinal Canal	0 Open	A Stem Cells, Embryonic	Z No Qualifier
No change	R Spinal Canal	0 Open	E Stem Cells, Somatic	0 Autologous 1 Nonautologous
No change	R Spinal Canal	3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	R Spinal Canal	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	R Spinal Canal	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance A Stem Cells, Embryonic B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	R Spinal Canal	3 Percutaneous	E Stem Cells, Somatic	0 Autologous 1 Nonautologous
No change	R Spinal Canal	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	R Spinal Canal	3 Percutaneous	S Gas	F Other Gas
No change	R Spinal Canal	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	S Epidural Space	3 Percutaneous	0 Antineoplastic	2 High-dose Interleukin-2 3 Low-dose Interleukin-2 4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	S Epidural Space	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	S Epidural Space	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	S Epidural Space	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	S Epidural Space	3 Percutaneous	S Gas	F Other Gas
No change	S Epidural Space	7 Via Natural or Artificial Opening	S Gas	F Other Gas
No change	T Peripheral Nerves and Plexi X Cranial Nerves	3 Percutaneous	3 Anti-inflammatory B Anesthetic Agent T Destructive Agent	Z No Qualifier
No change	T Peripheral Nerves and Plexi X Cranial Nerves	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	U Joints	0 Open	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
FY2025	U Joints	0 Open	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein C Other Substance
No change	U Joints	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	U Joints	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	U Joints	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	U Joints	3 Percutaneous	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein C Other Substance
No change	U Joints	3 Percutaneous	S Gas	F Other Gas
No change	U Joints	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	V Bones	0 Open	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein C Other Substance
No change	V Bones	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	V Bones	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective

No change	V Bones	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	V Bones	3 Percutaneous	G Other Therapeutic Substance	B Recombinant Bone Morphogenetic Protein C Other Substance
No change	V Bones	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	W Lymphatics	3 Percutaneous	0 Antineoplastic	5 Other Antineoplastic M Monoclonal Antibody
No change	W Lymphatics	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	W Lymphatics	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	W Lymphatics	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	Y Pericardial Cavity	3 Percutaneous	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	Y Pericardial Cavity	3 Percutaneous	2 Anti-infective	8 Oxazolidinones 9 Other Anti-infective
No change	Y Pericardial Cavity	3 Percutaneous	3 Anti-inflammatory 6 Nutritional Substance 7 Electrolytic and Water Balance Substance B Anesthetic Agent H Radioactive Substance K Other Diagnostic Substance N Analgesics, Hypnotics, Sedatives T Destructive Agent	Z No Qualifier
No change	Y Pericardial Cavity	3 Percutaneous	G Other Therapeutic Substance	C Other Substance
No change	Y Pericardial Cavity	3 Percutaneous	S Gas	F Other Gas
No change	Y Pericardial Cavity	4 Percutaneous Endoscopic	G Other Therapeutic Substance	C Other Substance
No change	Y Pericardial Cavity	7 Via Natural or Artificial Opening	0 Antineoplastic	4 Liquid Brachytherapy Radioisotope 5 Other Antineoplastic M Monoclonal Antibody
No change	Y Pericardial Cavity	7 Via Natural or Artificial Opening	S Gas	F Other Gas

D22

FY2025	<i>Section</i> D Radiation Therapy			
	<i>Body System</i> 2 Heart and Great Vessels			
	<i>Modality</i> 2 Stereotactic Radiosurgery			
Heading	<i>Treatment Site</i>	<i>Modality Qualifier</i>	<i>Isotope</i>	<i>Qualifier</i>
FY2025	8 Conduction Mechanism	D Stereotactic Other Photon Radiosurgery	Z None	Z None

X2K

No change	<i>Section</i> X New Technology			
	<i>Body System</i> 2 Cardiovascular System			
	<i>Operation</i> K Bypass: Altering the route of passage of the contents of a tubular body part			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
FY2025	A Atrium, Left	3 Percutaneous	0 Conduit through Coronary Sinus to Right Atrium	A New Technology Group 10
No change	B Radial Artery, Right C Radial Artery, Left	3 Percutaneous	1 Thermal Resistance Energy	7 New Technology Group 7
No change	H Femoral Artery, Right J Femoral Artery, Left	3 Percutaneous	D Conduit through Femoral Vein to Superficial Femoral Artery E Conduit through Femoral Vein to Popliteal Artery	9 New Technology Group 9

X2U

No change	<i>Section</i>	X	New Technology	
	<i>Body System</i>	2	Cardiovascular System	
	<i>Operation</i>	U	Supplement: Putting in or on biological or synthetic material that physically reinforces and/or augments the function of a portion of a body part	
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	4 Coronary Artery/Arteries	0 Open	7 Vein Graft Extraluminal Support Device(s)	9 New Technology Group 9
FY2025	9 Atrium, Right	3 Percutaneous	Y Intraluminal Device, Heterotopic Bioprosthetic Valve(s)	A New Technology Group 10
No change	Q Upper Extremity Vein, Right R Upper Extremity Vein, Left	0 Open	P Synthetic Substitute, Extraluminal Support Device	9 New Technology Group 9

XNS

No change	<i>Section</i>	X	New Technology	
	<i>Body System</i>	N	Bones	
	<i>Operation</i>	S	Reposition: Moving to its normal location, or other suitable location, all or a portion of a body part	
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	0 Lumbar Vertebra	0 Open	3 Magnetically Controlled Growth Rod(s)	2 New Technology Group 2
No change	0 Lumbar Vertebra	0 Open	C Posterior (Dynamic) Distraction Device	7 New Technology Group 7
No change	0 Lumbar Vertebra	3 Percutaneous	3 Magnetically Controlled Growth Rod(s)	2 New Technology Group 2
No change	0 Lumbar Vertebra	3 Percutaneous	C Posterior (Dynamic) Distraction Device	7 New Technology Group 7
No change	3 Cervical Vertebra	0 Open 3 Percutaneous	3 Magnetically Controlled Growth Rod(s)	2 New Technology Group 2
No change	4 Thoracic Vertebra	0 Open	3 Magnetically Controlled Growth Rod(s)	2 New Technology Group 2
No change	4 Thoracic Vertebra	0 Open	C Posterior (Dynamic) Distraction Device	7 New Technology Group 7
FY2025	4 Humeral Shaft, Right	0 Open	G Ring External Fixation Device with Automated Strut Adjustment	A New Technology Group 10
No change	4 Thoracic Vertebra	3 Percutaneous	3 Magnetically Controlled Growth Rod(s)	2 New Technology Group 2
No change	4 Thoracic Vertebra	3 Percutaneous	C Posterior (Dynamic) Distraction Device	7 New Technology Group 7
FY2025	4 Humeral Shaft, Right	3 Percutaneous	G Ring External Fixation Device with Automated Strut Adjustment	A New Technology Group 10
FY2025	5 Humeral Shaft, Left 6 Radius, Right 7 Radius, Left 8 Ulna, Right 9 Ulna, Left A Upper Femur, Right B Upper Femur, Left C Lower Femur, Right D Lower Femur, Left E Femoral Shaft, Right F Femoral Shaft, Left G Tibia, Right H Tibia, Left	0 Open 3 Percutaneous	G Ring External Fixation Device with Automated Strut Adjustment	A New Technology Group 10

XW0

No change	<i>Section</i>	X New Technology		
	<i>Body System</i>	W Anatomical Regions		
	<i>Operation</i>	0 Introduction: Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products		
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	0 Skin	X External	2 Anacaulase-bcdb	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	1 Daratumumab and Hyaluronidase-fihj	8 New Technology Group 8
No change	1 Subcutaneous Tissue	3 Percutaneous	2 Talquetamab Antineoplastic	9 New Technology Group 9
No change	1 Subcutaneous Tissue	3 Percutaneous	4 Teclistamab Antineoplastic	8 New Technology Group 8
No change	1 Subcutaneous Tissue	3 Percutaneous	6 Dasiglucagon	A New Technology Group 10
No change	1 Subcutaneous Tissue	3 Percutaneous	9 Satralizumab-mwge	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	1 Subcutaneous Tissue	3 Percutaneous	G REGN-COV2 Monoclonal Antibody H Other New Technology Monoclonal Antibody K Lerolimab Monoclonal Antibody	6 New Technology Group 6
No change	1 Subcutaneous Tissue	3 Percutaneous	L Elranatamab Antineoplastic	9 New Technology Group 9
No change	1 Subcutaneous Tissue	3 Percutaneous	S COVID-19 Vaccine Dose 1	6 New Technology Group 6
No change	1 Subcutaneous Tissue	3 Percutaneous	S Epcoritamab Monoclonal Antibody	9 New Technology Group 9
No change	1 Subcutaneous Tissue	3 Percutaneous	T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
No change	1 Subcutaneous Tissue	3 Percutaneous	V COVID-19 Vaccine Dose 3	7 New Technology Group 7
No change	1 Subcutaneous Tissue	3 Percutaneous	W Caplacizumab	5 New Technology Group 5
No change	1 Subcutaneous Tissue	3 Percutaneous	W COVID-19 Vaccine Booster	7 New Technology Group 7
No change	1 Subcutaneous Tissue	X External	2 Anacaulase-bcdb	7 New Technology Group 7
No change	2 Muscle	0 Open	D Engineered Allogeneic Thymus Tissue	8 New Technology Group 8
No change	2 Muscle	3 Percutaneous	S COVID-19 Vaccine Dose 1 T COVID-19 Vaccine Dose 2 U COVID-19 Vaccine	6 New Technology Group 6
No change	2 Muscle	3 Percutaneous	V COVID-19 Vaccine Dose 3 W COVID-19 Vaccine Booster X Tixagevimab and Cilgavimab Monoclonal Antibody Y Other New Technology Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	0 Brexanolone	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	0 Spesolimab Monoclonal Antibody	8 New Technology Group 8

No change	3 Peripheral Vein	3 Percutaneous	2 Nerinitide 3 Durvalumab Antineoplastic	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	3 Bentracimab, Ticagrelor Reversal Agent 4 Cefepime-taniborbactam Anti-infective	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	5 Mosunetuzumab Antineoplastic	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	5 Ceftobiprole Medocaril Anti-infective	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	6 Terlipressin	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	6 Afamitresgene Autoleucel Immunotherapy	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
No change	3 Peripheral Vein	3 Percutaneous	7 Trilaciclib	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	7 Tabelecleucel Immunotherapy	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	8 Lurbinectedin	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	8 Treosulfan	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	8 Obecabtagene Autoleucel	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	9 Inebilizumab-cdon	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	9 Odronektamab Antineoplastic	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	A Ciltacabtagene Autoleucel	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
No change	3 Peripheral Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	B Amivantamab Monoclonal Antibody	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	B Orca-T Allogeneic T-cell Immunotherapy	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	C Eculizumab	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	C Zanidatamab Antineoplastic	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	D Atezolizumab Antineoplastic	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	D Donislecel-jujn Allogeneic Pancreatic Islet Cellular Suspension	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
No change	3 Peripheral Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5

No change	3 Peripheral Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	F Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6
No change	3 Peripheral Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
No change	3 Peripheral Vein	3 Percutaneous	K Sulbactam-Durlobactam	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
FY2025	3 Peripheral Vein	3 Percutaneous	L Lileucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
FY2025	3 Peripheral Vein	3 Percutaneous	M Emapalumab-lzsg Anti-IFNy Monoclonal Antibody	A New Technology Group 10
FY2025	3 Peripheral Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
FY2025	3 Peripheral Vein	3 Percutaneous	N Tarlatamab-dlle Antineoplastic	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	P Glofitamab Antineoplastic	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	Q Posoleucel R Rezafungin	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	S Iobenguane I-131 Antineoplastic W Caplacizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	0 Brexanolone	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	0 Spesolimab Monoclonal Antibody	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	2 Nerinitide 3 Durvalumab Antineoplastic	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	3 Bentracimab, Ticagrelor Reversal Agent 4 Cefepime-taniborbactam Anti-infective	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	5 Narsoplimab Monoclonal Antibody	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	5 Mosunetuzumab Antineoplastic	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	5 Ceftobiprole Medocaril Anti-infective	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	6 Terlipressin	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	6 Afamitresgene Autoleucel Immunotherapy	8 New Technology Group 8

No change	4 Central Vein	3 Percutaneous	7 Coagulation Factor Xa, Inactivated	2 New Technology Group 2
No change	4 Central Vein	3 Percutaneous	7 Trilaciclib	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	7 Tabelecleucel Immunotherapy	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	8 Lurbinectedin	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	8 Treosulfan	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	8 Obecabtagene Autoleucel	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	9 Ceftolozane/Tazobactam Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	9 Inebilizumab-cdon	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	9 Odronektamab Antineoplastic	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	A Cefiderocol Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	A Ciltacabtagene Autoleucel	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	B Cytarabine and Daunorubicin Liposome Antineoplastic	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	B Omadacycline Anti-infective	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	B Amivantamab Monoclonal Antibody	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	B Orca-T Allogeneic T-cell Immunotherapy	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	C Eculizumab	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	C Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Autologous	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	C Zanidatamab Antineoplastic	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	D Atezolizumab Antineoplastic	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	E Remdesivir Anti-infective	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	E Etesevimab Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	3 New Technology Group 3
No change	4 Central Vein	3 Percutaneous	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	F Bamlanivimab Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	F Non-Chimeric Antigen Receptor T-cell Immune Effector Cell Therapy	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	G Sarilumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	G REGN-COV2 Monoclonal Antibody	6 New Technology Group 6
No change	4 Central Vein	3 Percutaneous	G Engineered Chimeric Antigen Receptor T-cell Immunotherapy, Allogeneic	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	H Tocilizumab	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	H Other New Technology Monoclonal Antibody	6 New Technology Group 6

No change	4 Central Vein	3 Percutaneous	H Axicabtagene Ciloleucel Immunotherapy J Tisagenlecleucel Immunotherapy K Idecabtagene Vicleucel Immunotherapy	7 New Technology Group 7
No change	4 Central Vein	3 Percutaneous	K Sulbactam-Durlobactam	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	L CD24Fc Immunomodulator	6 New Technology Group 6
FY2025	4 Central Vein	3 Percutaneous	L Lifleucel Immunotherapy M Brexucabtagene Autoleucel Immunotherapy	7 New Technology Group 7
FY2025	4 Central Vein	3 Percutaneous	M Emapalumab-Izsg Anti-IFNy Monoclonal Antibody	A New Technology Group 10
FY2025	4 Central Vein	3 Percutaneous	N Lisocabtagene Maraleucel Immunotherapy	7 New Technology Group 7
FY2025	4 Central Vein	3 Percutaneous	N Tarlatamab-dlle Antineoplastic	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	P Glofitamab Antineoplastic	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	Q Tagraxofusp-erzs Antineoplastic	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	Q Posoleucel R Rezafungin	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	S lobenguane I-131 Antineoplastic W Caplacizumab	5 New Technology Group 5
No change	5 Peripheral Artery	3 Percutaneous	T Melphalan Hydrochloride Antineoplastic	9 New Technology Group 9
No change	D Mouth and Pharynx	X External	3 Maribavir Anti-infective	8 New Technology Group 8
No change	D Mouth and Pharynx	X External	6 Lefamulin Anti-infective	6 New Technology Group 6
No change	D Mouth and Pharynx	X External	8 Uridine Triacetate	2 New Technology Group 2
No change	D Mouth and Pharynx	X External	F Other New Technology Therapeutic Substance	5 New Technology Group 5
No change	D Mouth and Pharynx	X External	J Quizartinib Antineoplastic	9 New Technology Group 9
No change	D Mouth and Pharynx	X External	K Sabizabulin	8 New Technology Group 8
No change	D Mouth and Pharynx	X External	M Baricitinib	6 New Technology Group 6
No change	D Mouth and Pharynx	X External	N SER-109	9 New Technology Group 9
No change	D Mouth and Pharynx	X External	R Fostamatinib	7 New Technology Group 7
No change	G Upper GI	7 Via Natural or Artificial Opening	3 Maribavir Anti-infective K Sabizabulin	8 New Technology Group 8
No change	G Upper GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
No change	G Upper GI	7 Via Natural or Artificial Opening	R Fostamatinib	7 New Technology Group 7
No change	G Upper GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6
No change	H Lower GI	7 Via Natural or Artificial Opening	3 Maribavir Anti-infective K Sabizabulin	8 New Technology Group 8
No change	H Lower GI	7 Via Natural or Artificial Opening	M Baricitinib	6 New Technology Group 6
No change	H Lower GI	7 Via Natural or Artificial Opening	R Fostamatinib	7 New Technology Group 7
No change	H Lower GI	7 Via Natural or Artificial Opening	X Broad Consortium Microbiota-based Live Biotherapeutic Suspension	8 New Technology Group 8
No change	H Lower GI	8 Via Natural or Artificial Opening Endoscopic	8 Mineral-based Topical Hemostatic Agent	6 New Technology Group 6

No change	J Coronary Artery, One Artery K Coronary Artery, Two Arteries L Coronary Artery, Three Arteries M Coronary Artery, Four or More Arteries	3 Percutaneous	H Paclitaxel-Coated Balloon Technology, One Balloon J Paclitaxel-Coated Balloon Technology, Two Balloons K Paclitaxel-Coated Balloon Technology, Three Balloons L Paclitaxel-Coated Balloon Technology, Four or More Balloons	A New Technology Group 10
No change	Q Cranial Cavity and Brain	3 Percutaneous	1 Eladocagene exuparvovec	6 New Technology Group 6
No change	U Joints	0 Open	G Vancomycin Hydrochloride and Tobramycin Sulfate Anti-Infective, Temporary Irrigation Spacer System	A New Technology Group 10
No change	V Bones	0 Open	P Antibiotic-eluting Bone Void Filler	7 New Technology Group 7
No change	V Bones	3 Percutaneous	W AGN1 Bone Void Filler	A New Technology Group 10

XW1

No change	Section X New Technology Body System W Anatomical Regions Operation 1 Transfusion: Putting in blood or blood products			
Heading	Body Part	Approach	Device / Substance / Technology	Qualifier
No change	3 Peripheral Vein	3 Percutaneous	2 Plasma, Convalescent (Nonautologous)	5 New Technology Group 5
No change	3 Peripheral Vein	3 Percutaneous	7 Marnetegrane Autotemcel	A New Technology Group 10
No change	3 Peripheral Vein	3 Percutaneous	B Betibeglogene Autotemcel C Omidubicel	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	D High-Dose Intravenous Immune Globulin E Hyperimmune Globulin	7 New Technology Group 7
Revise from	3 Peripheral Vein	3 Percutaneous	F OTL-103 G OTL-200	8 New Technology Group 8
Revise to	3 Peripheral Vein	3 Percutaneous	F OTL-103 G Atidarsagene Autotemcel	8 New Technology Group 8
No change	3 Peripheral Vein	3 Percutaneous	H Lovotibeglogene Autotemcel	9 New Technology Group 9
No change	3 Peripheral Vein	3 Percutaneous	J Exagamglogene Autotemcel	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	2 Plasma, Convalescent (Nonautologous)	5 New Technology Group 5
No change	4 Central Vein	3 Percutaneous	7 Marnetegrane Autotemcel	A New Technology Group 10
No change	4 Central Vein	3 Percutaneous	B Betibeglogene Autotemcel C Omidubicel	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	D High-Dose Intravenous Immune Globulin E Hyperimmune Globulin	7 New Technology Group 7
Revise from	4 Central Vein	3 Percutaneous	F OTL-103 G OTL-200	8 New Technology Group 8
Revise to	4 Central Vein	3 Percutaneous	F OTL-103 G Atidarsagene Autotemcel	8 New Technology Group 8
No change	4 Central Vein	3 Percutaneous	H Lovotibeglogene Autotemcel	9 New Technology Group 9
No change	4 Central Vein	3 Percutaneous	J Exagamglogene Autotemcel	8 New Technology Group 8

XXE

No change	Section X New Technology Body System X Physiological Systems Operation E Measurement: Determining the level of a physiological or physical function at a point in time			
Heading	<i>Body Part</i>	<i>Approach</i>	<i>Device / Substance / Technology</i>	<i>Qualifier</i>
No change	0 Central Nervous	X External	0 Intracranial Vascular Activity, Computer-aided Assessment	7 New Technology Group 7
No change	0 Central Nervous	X External	1 Intracranial Cerebrospinal Fluid Flow, Computer-aided Triage and Notification	A New Technology Group 10
No change	0 Central Nervous	X External	4 Brain Electrical Activity, Computer-aided Semiologic Analysis	8 New Technology Group 8
No change	2 Cardiac	X External	1 Output, Computer-aided Assessment	9 New Technology Group 9
No change	3 Arterial	X External	2 Pulmonary Artery Flow, Computer-aided Triage and Notification	7 New Technology Group 7
No change	3 Arterial	X External	5 Coronary Artery Flow, Quantitative Flow Ratio Analysis 6 Coronary Artery Flow, Computer-aided Valve Modeling and Notification	8 New Technology Group 8
No change	5 Circulatory	X External	2 Infection, Phenotypic Fully Automated Rapid Susceptibility Technology with Controlled Inoculum	A New Technology Group 10
No change	5 Circulatory	X External	3 Infection, Whole Blood Reverse Transcription and Quantitative Real-time Polymerase Chain Reaction	8 New Technology Group 8
FY2025	5 Circulatory	X External	4 Infection, Positive Blood Culture Small Molecule Sensor Array Technology 5 Immune Response, Whole Blood Cellular Assessment via Microfluidic Deformability	A New Technology Group 10
No change	5 Circulatory	X External	N Infection, Positive Blood Culture Fluorescence Hybridization for Organism Identification, Concentration and Susceptibility	6 New Technology Group 6
No change	5 Circulatory	X External	R Infection, Mechanical Initial Specimen Diversion Technique Using Active Negative Pressure T Intracranial Arterial Flow, Whole Blood mRNA V Infection, Serum/Plasma Nanoparticle Fluorescence SARS-CoV-2 Antibody Detection	7 New Technology Group 7
No change	5 Circulatory	X External	Y Infection, Other Positive Blood/Isolated Colonies Bimodal Phenotypic Susceptibility Technology	9 New Technology Group 9

No change	9 Nose	7 Via Natural or Artificial Opening	U Infection, Nasopharyngeal Fluid SARS-CoV-2 Polymerase Chain Reaction	7 New Technology Group 7
No change	B Respiratory	X External	Q Infection, Lower Respiratory Fluid Nucleic Acid-base Microbial Detection	6 New Technology Group 6